News | Radiopharmaceuticals and Tracers | May 22, 2017

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

Companies also announce the extension and expansion of their existing commercial supply agreement for nuclear products through 2020

Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18

May 22, 2017 — Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a definitive license agreement  for the continued Phase III development and worldwide commercialization of flurpiridaz F-18. Flurpiridaz F-18 is an investigational positron emission tomography (PET) myocardial perfusion imaging (MPI) agent that may improve the diagnosis of coronary artery disease (CAD), the most common form of heart disease. The definitive agreement follows the signing of a term sheet previously announced in late February 2017.

Under the definitive agreement, GE Healthcare will lead and fund the development program of flurpiridaz F-18, including the second Phase III clinical study. GE Healthcare will also have exclusive worldwide rights for the commercialization of flurpiridaz F-18. Lantheus will collaborate in both the development and commercialization process through a joint steering committee. Lantheus also maintains the option to co-promote the imaging agent in the United States.

Lantheus will receive a $5 million upfront cash payment and, if successful, up to $60 million in regulatory and sales milestones payments, plus double-digit royalties on U.S. sales and single-digit royalties on sales outside of the U.S.

Separately, the companies have also extended and expanded their current commercial agreement under which Lantheus will continue to supply GE Healthcare with TechneLite (Technetium Tc99m Generators), Gallium-67 (Gallium Citrate Ga 67 Injection) and Xenon-133 (Xenon Xe 133 Gas) through Dec. 31, 2020.

For more information: www.gehealthcare.com, www.lantheus.com

Related Content

Videos | Cardiac Imaging | September 10, 2018
Leslee Shaw, Ph.D., professor of cardiology and rad
Arterys collaborated with GE Healthcare to create the ViosWorks software to cardiac MRI analysis.

Arterys collaborated with GE Healthcare to create the ViosWorks software. The software integrates artificial intelligence to speed workflow and perform a full 3-D chest volume scan with myocardium motion, blood flow, time and fully automated quantification.

Feature | Cardiac Imaging | March 30, 2018 | Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used
New Policy Decisions Give Millions Access to HeartFlow FFRct Analysis
News | Cardiac Imaging | February 01, 2018
February 1, 2018 – HeartFlow announced that seven new commercial payers issued positive medical policies covering the
Clear detail of the in-stent restenosis can be seen in this image from the new high-resolution Canon Precision CT system. RSNA 2017, #RSNA2017, #RSNA17

Clear detail of the in-stent restenosis can be seen in this image from the new high-resolution Canon Aquilion Precision CT system.

Feature | Cardiac Imaging | January 23, 2018 | Dave Fornell
Medical imaging plays a key role in cardiology, and most of the newest radiology technology advances are first unveil
Philips Introduces Technology Maximizer Program for Imaging Equipment Upgrades
Technology | Cardiac Imaging | January 17, 2018
Philips recently announced the launch of Technology Maximizer, a cross-modality program designed to boost the clinical...
Videos | Cardiac Imaging | December 29, 2017
ITN and DAIC Editor Dave Fornell takes a tour of some of the most interesting new medical imaging technologies on the
Siemens Healthineers Introduces Share360 Tailored Service Portfolio
News | Cardiac Imaging | November 10, 2017
To address the specific needs of medical imaging clinical engineering departments nationwide, Siemens Healthineers has...
HeartFlow's FFR-CT (FFRct) analysis software can create a virtual FFR to assess coronary artery disease.

HeartFlow's FFR-CT analysis software uses a computed tomography scan and supercomputing fluid dynamics software to create a noninvasive, virtual FFR map of the entire coronary artery tree to determine the flow-limiting severity of ant lesions. 

News | Cardiac Imaging | November 06, 2017
November 6, 2017 – The Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory P
Philips Announces Findings of Patient Experience in Imaging Research
News | Cardiac Imaging | October 24, 2017
Philips recently announced the key findings of its research focused on the patient experience in diagnostic imaging...
Overlay Init